oseltamivir in GNE-associated thrombocytopenia. Approaches: Sialylation of platelets, granulocytes, lymphocytes and monocytes was established by movement cytometry inside the proband and healthier controls (n = five), applying Sambucus nigra lectin (SNA) and Maackia amurensis lectin II (MAL II). Platelet sialylation was reassessed during the proband following treatment with oseltamivir (75 mg twice day by day, offlabel use). Informed consent was obtained from all participants. The research was accepted from the regional ethical committee. Outcomes: Sialylation of platelets and leukocytes was markedly decreased during the proband in contrast using the balanced controls, steady having a deleterious effect with the compound heterozygous variants in GNE (Figure 1). Platelet sialylation was persistently decreased soon after 18 days of remedy with oseltamivir, and no clinically significant elevation from the platelet counts could possibly be observed (Figure 1, Figure 2). N. Podoplelova1,two; E. Popova3,1; P. Zharkov2; D. Fedorova2; A. Greinacher4; M. Panteleev1,two,Conclusions: We report two compound heterozygous variants in GNE creating significant macrothrombocytopenia, as a consequence of decreased platelet sialylation. Therapy with oseltamivir didn’t show to be efficient for mitigating the GNE-associated thrombocytopenia identified within the patient.PB0872|GCN5/PCAF Inhibitor list Immunofluorescence GlyT1 Inhibitor Species staining of Blood Smears to the Diagnostics of Platelet Ailments: A Single-center Experience inside a Pediatric HospitalCenter for Theoretical Issues of Physicochemical Pharmacology,Moscow, Russian Federation; 2Dmitry Rogachev National Health care Investigate Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation; 3Lomonosov Moscow State University, Moscow, Russian Federation; 4Institut f Immunologie und Transfusionsmedizin, Universit smedizin Greifswald, Greifswald, Germany Background: The approach of immunofluorescence staining of blood smears is actually a recently created (Greinacher et al. J Thromb Haemost 2017; 15: 1511521) strategy of remote diagnostics of several platelet pathologies like MYH9 disorders/MYH9-related disease, biallelic Bernard-Soulier syndrome, Glanzmann thrombastenia, and gray platelet syndrome, and others. We report here experience of introducing this method from the Nationwide Research Center of Pediatric Hematology, Oncology and Immunology named right after Dmitry Rogachev (Moscow, Russia), and that is the principle national pediatric hematology hospital that provides diagnosis and therapy to small children with blood problems through the entire nation. Aims: Our examine aimed to transfer this fairly labor-intensive and skill-sensitive methodology, to introduce during the schedule laboratory practice, and to complete its validation. Techniques: Blood smears from healthful donors and patients were ready applying the normal strategy established around the world, air-dried, and storage. Citrate anticoagulated blood was employed for planning. For immunofluorescence labeling was utilized principal antibodies (Myosin, LAMP 1 (H5G11), LAMP 2 (H4B4), VWF, P-Selectin (CD62P), CD63 (delta-granules), Ib/IX CD42a (FMC25), IIb/IIIa CD41 P2, 1-Tubulin (2.1.), -Tubulin (RM113)) and fluorescence labeling secondary antibodies. Blood smears have been assessed by immunofluorescence microscopy. Outcomes: Patients with unique platelet problems (9 individuals with MYH9 disorder, seven individuals with Wiskott-Aldrich syndrome, two patients with Bernard-Soulier syndrome, 2 individuals Hermansky-Pudlak syndrome,one patient with gray platelets syndrome, one patient with Glanzmann th